Climb Bio, Inc.

Contributing Author

Recent Articles by Climb Bio, Inc.

Sep-03	Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy CLYM GlobeNewswire
Sep-02	Climb Bio to Present at Upcoming Investor Conferences CLYM GlobeNewswire
Aug-06	Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates CLYM +12.27% GlobeNewswire
Jun-11	Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 CLYM GlobeNewswire
Jun-05	Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development CLYM GlobeNewswire
May-26	Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 CLYM GlobeNewswire
May-14	Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress CLYM GlobeNewswire
May-12	Climb Bio to Present at Upcoming Investor Conferences CLYM GlobeNewswire
May-07	Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates CLYM GlobeNewswire
May-05	Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts CLYM +18.16% GlobeNewswire
Apr-28	Climb Bio, Inc. Announces $110.0 Million Private Placement CLYM GlobeNewswire
Apr-08	Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 CLYM GlobeNewswire
Apr-07	Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy CLYM GlobeNewswire
Mar-05	Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates CLYM GlobeNewswire
Feb-05	Climb Bio to Present at Upcoming Investor Conferences CLYM -7.92% GlobeNewswire
Jan-08	Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 CLYM +9.05% GlobeNewswire
Nov-25	Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CLYM GlobeNewswire
Nov-06	Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates CLYM GlobeNewswire
Nov-03	Climb Bio to Present at Upcoming Investor Conferences CLYM GlobeNewswire
Oct-21	Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy CLYM GlobeNewswire
Oct-17	Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 CLYM GlobeNewswire
Oct-01	Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer CLYM GlobeNewswire
Sep-29	Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN CLYM -6.57% GlobeNewswire
Sep-04	Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025 CLYM GlobeNewswire
Aug-25	UPDATE - Climb Bio to Present at Upcoming September 2025 Investor Conferences CLYM CLYM -6.05% GlobeNewswire
Aug-25	Climb Bio to Present at Upcoming September 2025 Investor Conferences CLYM GlobeNewswire
Aug-12	Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates CLYM GlobeNewswire
Jun-18	Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer CLYM GlobeNewswire
May-19	Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CLYM GlobeNewswire
May-14	Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates CLYM -7.87% GlobeNewswire

Climb Bio, Inc.

Recent Articles by Climb Bio, Inc.

Upgrade your Finviz experience